Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits

Klára Csete, J. Papp

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Hypertension associated with excessive liberation of circulating and tissue catecholamines is an independent risk factor for further cardiovascular complications and an important predictor of stroke. Moxonidine is a centrally acting antihypertensive drug with potent action on I1- imidazoline receptors. It inhibits catecholamine release and is therefore expected to exert an antiadrenergic effect at various levels in the regulation of the cardiovascular system. The aim of this study was to investigate the effect of moxonidine (0.025-0.1 mg/kg, i.v.) on the normal and unilateral carotid occlusion-induced impaired corticocerebral blood flow (cCBF) determined by hydrogen polarography, on mean arterial blood pressure (MABP) and heart rate (HR) in conscious rabbits. Moxonidine produced a reduction of MABP and HR. On the other hand, after administration of the drug, a significant increase in the normal and impaired cCBF was observed. Because the improvement in cCBF was conspicuous in both normal and ischemic conditions, moxonidine might be beneficial not only in the treatment of hypertension but also in the management of cerebral ischemia.

Original languageEnglish
Pages (from-to)417-421
Number of pages5
JournalJournal of Cardiovascular Pharmacology
Volume35
Issue number3
DOIs
Publication statusPublished - 2000

Fingerprint

moxonidine
Cerebral Cortex
Arterial Pressure
Rabbits
Catecholamines
Heart Rate
Polarography
Hypertension
Adrenergic Antagonists
Cardiovascular System
Brain Ischemia
Antihypertensive Agents
Hydrogen
Stroke

Keywords

  • Conscious rabbits
  • Corticocerebral blood flow
  • Hydrogen polarography
  • I
  • Imidazoline-receptors
  • Moxonidine

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits. / Csete, Klára; Papp, J.

In: Journal of Cardiovascular Pharmacology, Vol. 35, No. 3, 2000, p. 417-421.

Research output: Contribution to journalArticle

@article{8430a3cafeac4ce889c9403db7725d20,
title = "Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits",
abstract = "Hypertension associated with excessive liberation of circulating and tissue catecholamines is an independent risk factor for further cardiovascular complications and an important predictor of stroke. Moxonidine is a centrally acting antihypertensive drug with potent action on I1- imidazoline receptors. It inhibits catecholamine release and is therefore expected to exert an antiadrenergic effect at various levels in the regulation of the cardiovascular system. The aim of this study was to investigate the effect of moxonidine (0.025-0.1 mg/kg, i.v.) on the normal and unilateral carotid occlusion-induced impaired corticocerebral blood flow (cCBF) determined by hydrogen polarography, on mean arterial blood pressure (MABP) and heart rate (HR) in conscious rabbits. Moxonidine produced a reduction of MABP and HR. On the other hand, after administration of the drug, a significant increase in the normal and impaired cCBF was observed. Because the improvement in cCBF was conspicuous in both normal and ischemic conditions, moxonidine might be beneficial not only in the treatment of hypertension but also in the management of cerebral ischemia.",
keywords = "Conscious rabbits, Corticocerebral blood flow, Hydrogen polarography, I, Imidazoline-receptors, Moxonidine",
author = "Kl{\'a}ra Csete and J. Papp",
year = "2000",
doi = "10.1097/00005344-200003000-00011",
language = "English",
volume = "35",
pages = "417--421",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits

AU - Csete, Klára

AU - Papp, J.

PY - 2000

Y1 - 2000

N2 - Hypertension associated with excessive liberation of circulating and tissue catecholamines is an independent risk factor for further cardiovascular complications and an important predictor of stroke. Moxonidine is a centrally acting antihypertensive drug with potent action on I1- imidazoline receptors. It inhibits catecholamine release and is therefore expected to exert an antiadrenergic effect at various levels in the regulation of the cardiovascular system. The aim of this study was to investigate the effect of moxonidine (0.025-0.1 mg/kg, i.v.) on the normal and unilateral carotid occlusion-induced impaired corticocerebral blood flow (cCBF) determined by hydrogen polarography, on mean arterial blood pressure (MABP) and heart rate (HR) in conscious rabbits. Moxonidine produced a reduction of MABP and HR. On the other hand, after administration of the drug, a significant increase in the normal and impaired cCBF was observed. Because the improvement in cCBF was conspicuous in both normal and ischemic conditions, moxonidine might be beneficial not only in the treatment of hypertension but also in the management of cerebral ischemia.

AB - Hypertension associated with excessive liberation of circulating and tissue catecholamines is an independent risk factor for further cardiovascular complications and an important predictor of stroke. Moxonidine is a centrally acting antihypertensive drug with potent action on I1- imidazoline receptors. It inhibits catecholamine release and is therefore expected to exert an antiadrenergic effect at various levels in the regulation of the cardiovascular system. The aim of this study was to investigate the effect of moxonidine (0.025-0.1 mg/kg, i.v.) on the normal and unilateral carotid occlusion-induced impaired corticocerebral blood flow (cCBF) determined by hydrogen polarography, on mean arterial blood pressure (MABP) and heart rate (HR) in conscious rabbits. Moxonidine produced a reduction of MABP and HR. On the other hand, after administration of the drug, a significant increase in the normal and impaired cCBF was observed. Because the improvement in cCBF was conspicuous in both normal and ischemic conditions, moxonidine might be beneficial not only in the treatment of hypertension but also in the management of cerebral ischemia.

KW - Conscious rabbits

KW - Corticocerebral blood flow

KW - Hydrogen polarography

KW - I

KW - Imidazoline-receptors

KW - Moxonidine

UR - http://www.scopus.com/inward/record.url?scp=0034004289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034004289&partnerID=8YFLogxK

U2 - 10.1097/00005344-200003000-00011

DO - 10.1097/00005344-200003000-00011

M3 - Article

VL - 35

SP - 417

EP - 421

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -